Qiagen

Global Industry Analysts Predicts the World Precision Medicine Software Market to Reach $2.4 Billion by 2026

Retrieved on: 
Tuesday, August 31, 2021
Cloud, Engineered Software Inc., CAGR, Qiagen, LLC, Foundation Medicine, Health care, Growth, Software, Forecasting, Human Longevity, Geography, Research, Oncology, Marketing, Internet, Academic institution, Degenerative disease, Intelligence, SAN, Longevity, Sunquest Information Systems, Players, Precision medicine, COVID-19, GIA, Pharmaceutical industry, Pet

SAN FRANCISCO, Aug. 31, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Precision Medicine Software - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, Aug. 31, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Precision Medicine Software - Global Market Trajectory & Analytics" .
  • Preview Registry
    Amid the COVID-19 crisis, the global market for Precision Medicine Software estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$2.4 Billion by 2026, growing at a CAGR of 10.1% over the analysis period.
  • The U.S. Market is Estimated at $390 Million in 2021, While China is Forecast to Reach $480.2 Million by 2026
    The Precision Medicine Software market in the U.S. is estimated at US$390 Million in the year 2021.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

QIAGEN Reports Full Results for Q2 and H1 2021

Retrieved on: 
Thursday, July 29, 2021
Medical devices, Health, Genetics, Research, Science, Biotechnology, Medical software, Qiagen, United States dollar, Economies, Currency

Net sales rose 28% (+24% at constant exchange rates, CER) to $567.3 million in Q2 2021 and above the outlook for about 20% CER growth.

Key Points: 
  • Net sales rose 28% (+24% at constant exchange rates, CER) to $567.3 million in Q2 2021 and above the outlook for about 20% CER growth.
  • Currency movements against the U.S. dollar had a positive impact of about four percentage points on sales at actual rates in Q2 2021 over the year-ago period.
  • For the first half of 2021, net sales rose 39% (+35% CER) to $1.135 billion.
  • As of June 30, 2021, QIAGEN employed more than 5,900 people in over 35 locations worldwide.

2021 Worldwide Molecular Diagnostics Tests Market Report: 10th Edition - ResearchAndMarkets.com

Retrieved on: 
Friday, July 23, 2021
Biotechnology, Genetics, Health, Branches of biology, Medicine, Medical tests, Life sciences, Biotechnology, Medical genetics, Molecular diagnostics, Medical diagnosis, Qiagen, DiaSorin

Clinical molecular tests available for infectious disease testing offer a combination of high sensitivity, specificity and low turnaround time advantages.

Key Points: 
  • Clinical molecular tests available for infectious disease testing offer a combination of high sensitivity, specificity and low turnaround time advantages.
  • This report reviews the current makeup of the molecular diagnostics market in cancer, including its notable products and geographical segmentation.
  • The current market is largely composed of tissue-based tests, companion assays, and tests for the prognosis and diagnosis of specific cancer types.
  • World Molecular Diagnostics Market analyzes the developments in most significant markets within molecular inherited disease diagnostics.

QIAGEN N.V. Conference Call on July 13 to Discuss Preliminary Q2 2021 Results

Retrieved on: 
Monday, July 12, 2021
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Medical software, Qiagen, Life sciences, Biology, Biotechnology, Branches of biology, Bioinformatics, Molecular diagnostics, Molecular biology, Biomatrica

Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials.

Key Points: 
  • Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials.
  • Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights.
  • QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).
  • As of March 31, 2021, QIAGEN employed approximately 5,700 people in over 35 locations worldwide.

QIAGEN announces preliminary Q2 2021 results exceeding outlook, updates full-year 2021 outlook for declining COVID-19 test trends and plans new $100 million share repurchase program

Retrieved on: 
Monday, July 12, 2021
Biotechnology, Other Health, Health, Genetics, Pharmaceutical, Tuberculosis, Medical software, Qiagen, QuantiFERON, Repurchase agreement, Companies, Economy of Germany

Americas: Strongest regional performance in Q2 2021 driven by over 50% CER growth in the United States and QuantiFERON-TB.

Key Points: 
  • Americas: Strongest regional performance in Q2 2021 driven by over 50% CER growth in the United States and QuantiFERON-TB.
  • Higher sales were also seen in Australia and South Korea, more than absorbing a double-digit CER decline in India.
  • QIAGEN will provide regular updates on the progress of the repurchase program in the Investor Relations section at www.qiagen.com .
  • QIAGEN also uses adjusted results when comparing current performance to historical operating results, which have consistently been presented on an adjusted basis.

QIAGEN’s NeuMoDx™ HAdV Quant Assay Secures CE-IVD Certification for Automated Testing to Detect Human Adenovirus Infections

Retrieved on: 
Thursday, July 8, 2021
Medical Supplies, Biotechnology, Health, General Health, Pharmaceutical, Medical devices, Research, Infectious diseases, Surgery, Genetics, Science, Biology, Medical software, Qiagen, Branches of biology, Adenoviridae, Life sciences, Molecular diagnostics, IVD, Immunochemistry

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its NeuMoDx HAdV Quant Assay for the identification and quantification of human adenovirus (HAdV) DNA has received CE-IVD certification for the European Union and other countries that accept this marking.

Key Points: 
  • QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its NeuMoDx HAdV Quant Assay for the identification and quantification of human adenovirus (HAdV) DNA has received CE-IVD certification for the European Union and other countries that accept this marking.
  • This milestone marks the 15th assay available on the NeuMoDx 96 and 288 Molecular Systems, which is considered one of the broadest menus available among competitors.
  • Testing for the human adenovirus is critical since it can cause severe respiratory and other diseases in patients with weakened immune systems, a common consequence of organ transplantation.
  • The new HAdV Quant Assay was developed in partnership with Sentinel Diagnostics, an IVD company engaged in the development and production of diagnostic kits for Clinical Chemistry, Immunochemistry and Molecular Diagnostics.

QIAGEN launches the Workflow Configurator to help life science researchers simplify and optimize their laboratory experiments

Retrieved on: 
Wednesday, July 7, 2021
Science, Software, Biotechnology, Research, Pharmaceutical, Health, Data management, Technology, Medical software, Qiagen, Application software, Articles, Business, Workflow, QIA, Configurator

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the Workflow Configurator, enabling researchers in the life sciences to easily and quickly find the best solutions to optimize their experiments.

Key Points: 
  • QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the Workflow Configurator, enabling researchers in the life sciences to easily and quickly find the best solutions to optimize their experiments.
  • In seconds, the configurator sorts through hundreds of potential products to find the most suitable workflow and associated products.
  • The Workflow Configurator which is available at https://www.qiagen.com/workflow-configurator/workflows also offers direct purchase and sales support.
  • QIAGEN knows discoveries take careful workflow planning and optimization, and we design our solutions with this in mind.

Global Clinical Laboratory Market Analysis Report 2021-2026 with Impacts/Changes of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Biotechnology, Health, Science, Other Science, Research, Companies, Life sciences, Industry economics), Clinical pathology, Corning Inc., Medical diagnosis, Medical laboratory, Qiagen, Ortho Clinical Diagnostics, Quest Diagnostics, LabCorp, Agilent Technologies

The "Global Clinical Laboratory Market - Analysis By Test, End User, By Region, By Country (2021 Edition): Market Insights and Forecast with impact of COVID-19 (2021-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Clinical Laboratory Market - Analysis By Test, End User, By Region, By Country (2021 Edition): Market Insights and Forecast with impact of COVID-19 (2021-2026)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Clinical Laboratory Market is estimated at USD 23.9 billion in the year 2020.
  • The report analyses the Clinical Laboratories Market by End User (Hospital Based Laboratories, Clinical Based Laboratories, Independent Laboratories, Reference Laboratories, Others).
  • The companies analysed in the report include Abbott Laboratories, Ortho Clinical Diagnostics, Charles River Laboratories Inc., SGS S.A., QIAGEN, OPKO Health Inc., Sartorius Ag, Laboratory Corporation of America Holding, Quest Diagnostics, Eurofins Scientific
    4 Global Clinical Laboratory Market: Sizing and Forecast
    4 1 Global Clinical Laboratory Market Size, By Value, Year 2016-2026
    5 Global Clinical Laboratory Market Segmentation - By Test, By End User
    5 1 Competitive Scenario of Global Clinical Laboratory Market: By Test
    5 2 Competitive Scenario of Global Clinical Laboratory Market: By End user
    6 Global Clinical Laboratory Market: Regional Analysis
    7 North America Clinical Laboratory Market: An Analysis (2016-2026)
    8 Europe Clinical Laboratory Market: An Analysis (2016-2026)
    9 Asia Pacific Clinical Laboratory Market: An Analysis (2016-2026)
    10 LAMEA Clinical Laboratory Market: An Analysis (2016-2026)

QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS Technology

Retrieved on: 
Thursday, July 1, 2021
Oncology, Health, Other Science, Pharmaceutical, Science, Biotechnology, Medicine, Clinical medicine, Medical software, Qiagen, Cancer screening, Liquid biopsy, Biopsy, QIAGEN, Sysmex, QIAGEN, SYSMEX

The alliance aims to foster collaborations with pharmaceutical companies for the development of drug treatments for cancer and promote early clinical adoption of ultra-sensitive liquid biopsy companion diagnostics.

Key Points: 
  • The alliance aims to foster collaborations with pharmaceutical companies for the development of drug treatments for cancer and promote early clinical adoption of ultra-sensitive liquid biopsy companion diagnostics.
  • Cancer companion-diagnostics products will be launched by QIAGEN and Sysmex in various regions of the world.
  • Liquid biopsy addresses these challenges and, in combination with sensitive NGS, allows the evaluation of patients at different points of their cancer treatment.
  • The alliance with QIAGEN promises Sysmex a great application for Sysmexs Plasma-Safe-SeqS technology, which can detect gene mutations of cancer in blood with ultra-high sensitivity.

Statement from Davidson Kempner regarding Qiagen

Retrieved on: 
Wednesday, June 30, 2021
Finance, Money, Financial markets, Investment, Hedge funds, Alternative investment management companies, Institutional investors, Davidson Kempner Capital Management, Corporate finance, Arbitrage, Valuation, Qiagen

This has created a credibility issue that is currently reflected in Qiagen's steep valuation discount to peers and its own historic multiples, and negatively impacts the business.

Key Points: 
  • This has created a credibility issue that is currently reflected in Qiagen's steep valuation discount to peers and its own historic multiples, and negatively impacts the business.
  • Qiagen AGMs typically record 95%+ votes in favour of the reappointment of Board members, unless there have been specific concerns.
  • Davidson Kempner Capital Management LP is a global institutional alternative asset management firm, founded in 1983, with over 400 team members and approximately $37.7 billion in assets under management (estimate as of 1 June, 2021).
  • The Firm's investment strategies include Distressed, Merger Arbitrage, Long/Short Equities, Convertible Arbitrage and Long/Short Credit.